Vermillion's Q2 Revenues Flat at $323,000

NEW YORK (Genomeweb News) – Vermillion reported after the close of the market Wednesday that its second quarter revenues were essentially flat year over year at $323,000 versus $321,000 in Q2 2012.

The company posted product revenue of $210,000, up 1 percent from $208,000 year over year. That revenue was based on 4,184 OVA1 ovarian cancer tests performed in Q2 2013 versus 4,150 tests performed in the year-ago period.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.